Effects of human induced pluripotent stem cell-derived intestinal organoids on colitis-model mice

Nakanishi, Anna; Toyama, Satoshi; Onozato, Daichi; Watanabe, Chihiro; Hashita, Tadahiro; Iwao, Takahiro; Matsunaga, Tamihide

doi:10.1016/j.reth.2022.08.004

Cited by 6 publications

(9 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An innovative protocol has been published for the transplantation of iPSCs-derived HIOs into a mouse model of colitis. In this study, two types of HIOs, HIOs-A and HIOs-B, were generated via suspension culture with and without small molecules, including a TGF-β pathway inhibitor (A-83-01), a MEK inhibitor (PD98059), an DNA methylation inhibitor (5-Aza) and a Notch activation blocker (DAPT) ( Table 3 ) ( 20 ). HIOs-A without coculture with the small molecules had more intestinal stem cells expressing Lgr5, while HIOs-B cultured with the small molecules had more intestinal mature cells, including epithelial and secretory cells ( 20 ).…”

Section: Ibdmentioning

confidence: 99%

“…In this study, two types of HIOs, HIOs-A and HIOs-B, were generated via suspension culture with and without small molecules, including a TGF-β pathway inhibitor (A-83-01), a MEK inhibitor (PD98059), an DNA methylation inhibitor (5-Aza) and a Notch activation blocker (DAPT) ( Table 3 ) ( 20 ). HIOs-A without coculture with the small molecules had more intestinal stem cells expressing Lgr5, while HIOs-B cultured with the small molecules had more intestinal mature cells, including epithelial and secretory cells ( 20 ). Animals in the HIO-A group had a faster recovery (body weight and clinical symptoms with lower acid mucopolysaccharide level and less colonic stricture) than both HIO-B and natural healing group after transplantation into colon tissue of acute colitis mice model induced by DSS ( 20 ).…”

Section: Ibdmentioning

confidence: 99%

“…HIOs-A without coculture with the small molecules had more intestinal stem cells expressing Lgr5, while HIOs-B cultured with the small molecules had more intestinal mature cells, including epithelial and secretory cells ( 20 ). Animals in the HIO-A group had a faster recovery (body weight and clinical symptoms with lower acid mucopolysaccharide level and less colonic stricture) than both HIO-B and natural healing group after transplantation into colon tissue of acute colitis mice model induced by DSS ( 20 ). In addition, HIO-A and HIO-B decreased the production of pro-inflammatory cytokines in the colon at different degrees ( 20 ).…”

Section: Ibdmentioning

confidence: 99%

“…Cells from autologous iPSCs may reduce the risk of immune rejection and relieve diseases caused by single gene defects through gene-editing technology ( 17 ). In preclinical studies, iPSCs-derived neural precursor cells (NPCs), intestinal organoids and islet cells were transplanted into animal models with MS, IBD and T1D and showed some therapeutic effects ( 18 – 20 ). Some investigators also presented a strategy of iPSCs differentiation into regulatory T cells (Tregs) and regulatory dendritic cells against autoimmunity in iPSCs-based immunotherapy ( 21 , 22 ).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Research progress of autoimmune diseases based on induced pluripotent stem cells

Ren,

Jiang,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Autoimmune diseases can damage specific or multiple organs and tissues, influence the quality of life, and even cause disability and death. A ‘disease in a dish’ can be developed based on patients-derived induced pluripotent stem cells (iPSCs) and iPSCs-derived disease-relevant cell types to provide a platform for pathogenesis research, phenotypical assays, cell therapy, and drug discovery. With rapid progress in molecular biology research methods including genome-sequencing technology, epigenetic analysis, ‘-omics’ analysis and organoid technology, large amount of data represents an opportunity to help in gaining an in-depth understanding of pathological mechanisms and developing novel therapeutic strategies for these diseases. This paper aimed to review the iPSCs-based research on phenotype confirmation, mechanism exploration, drug discovery, and cell therapy for autoimmune diseases, especially multiple sclerosis, inflammatory bowel disease, and type 1 diabetes using iPSCs and iPSCs-derived cells.

show abstract

Section: Ibdmentioning

confidence: 99%

Section: Ibdmentioning

confidence: 99%

Section: Ibdmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Research progress of autoimmune diseases based on induced pluripotent stem cells

Ren,

Jiang,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…UC has worldwide distribution and affects an increasing number of people (3) . UC is characterized by significant disparity in disease severity levels (1) , and trends in different countries and by repeated remissions and relapses however, its treatment still has limited clinical success (3) .…”

Section: Introductionmentioning

confidence: 99%

Combination of High Fecal Calprotectin and High Scores of The Frequency of Night Motion and Urgency Might Discriminate Ulcerative Colitis Patients with Bad Quality of Life and Fatigue in Ulcerative Colitis Patients

El-Ansary¹,

Ali²,

El-Ansary³

2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Ulcerative colitis (UC) has worldwide distribution and affects an increasing number of people. Calprotectin (CP) was found to be used to discriminate high fatigue scores among UC patients. Objective:The aim of the current study is the assessment of the relation between ulcerative colitis (UC) disease activity scores and fecal calprotectin (FCP) levels and patients' quality of life (QOL) and sensation of body fatigue. Patients and methods: A total of 51 newly clinically diagnosed UC patients underwent evaluation of disease activity using the Simple Clinical Colitis Activity Index (SCCAI) and Mayo's Disease Activity Index (DAI) and for QOL and fatigue using the Inflammatory Bowel Disease-QOL and IBD-Fatigue Questionnaires (IBD-QOL-Q, IBD-FQ). Serum C-reactive protein (CRP) and FCP levels were estimated. Results: About 53% of patients had 3-4 UC diagnostic criteria with median values for SCCAI score and Mayo's DAI of was 6 (IQR=3-8) and 6 (IQR=5-9), respectively. A total of 27 patients had scores on IBD-QOL-Q and IBD-FQ above the median value. A total of 28 patients had serum CRP ≥9 and 26 patients had FCP level ≥150. Regression analysis defined high score for the night bowel (NB) motion frequency (β=0.476, P<0.001), rectal bleeding (β=0.269, P<0.001), old age (β=0.165 P=0.014), IBD-FQ (β=0.180, P=0.022) and urgency (β=0.180, P=0.022) as predictors for high IBD-QOL-Q score and the Receiver Operating Characteristic (ROC) curve analysis defined high score for NB motion frequency as the significant predictor for a score of 98 on IBD-QOL-Q. Combined scoring of the frequency of number of bleeding motions, stool urgency, rectal bleeding and high FCP levels could be used to discriminate patients with high fatigue scores and FCP can discriminate patients with score >60 with PPV of 85.29% (95%CI: 73.79-84.11%) and accuracy rate of 74.51% (95%CI: 60.37-85.67%). Conclusion: IBD badly affects patients QOL and this effect is related to disease severity and severity of differential symptoms especially the NB frequency, urgency and severity of rectal bleeding.

show abstract

Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors

He,

Weng,

Liu

et al. 2023

Stem Cell Rev and Rep

View full text Add to dashboard Cite

In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from modeling to treatment. Induced pluripotent stem cells derived from somatic cells, cancer cell lines, primary tumors, and individuals with an inherited propensity to develop cancer have shown great potential in cancer modeling, cell therapy, immunotherapy, and understanding tumor progression. This review summarizes the evolution of induced pluripotent stem cells technology and its applications in malignant solid tumor. Additionally, we discuss potential obstacles to induced pluripotent stem cell technology. Graphical Abstract

show abstract

Effects of human induced pluripotent stem cell-derived intestinal organoids on colitis-model mice

Cited by 6 publications

References 42 publications

Research progress of autoimmune diseases based on induced pluripotent stem cells

Research progress of autoimmune diseases based on induced pluripotent stem cells

Combination of High Fecal Calprotectin and High Scores of The Frequency of Night Motion and Urgency Might Discriminate Ulcerative Colitis Patients with Bad Quality of Life and Fatigue in Ulcerative Colitis Patients

Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors

Contact Info

Product

Resources

About